Food and Drug Administration Announces the Availability of New Draft Guidance for Industry: “E6(R3) Guideline for Good Clinical Practic.”
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled “E6(R3) Guideline for Good Clinical Practice.” The draft guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The draft guidance outlines modernized Good Clinical Practice considerations to guide thoughtful design and responsible conduct of clinical trials in a manner that ensures participant safety and the reliability of trial results. This draft guidance encourages innovation, focuses on quality, and establishes proportionate and risk-based approaches for conducting clinical trials, while minimizing unnecessary complexities. The draft guidance is intended to provide flexible, modern, and clear Good Clinical Practice for conducting clinical trials
- Explanatory Video – ICH E6(R3) Guideline – Good Clinical Practice
- Updated Guidelines – ICH E6 (R3) – Good Clinical Practice (2025)